Albireo Pharma Inc
ALBO
Market Cap$0
Close$
$57.06
29.2% upside
Current Fair Value
29.2% upsideUndervalued by 29.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $-222,476,000.00 |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-6.77 |
| Beta | 0.0 |
| Outstanding Shares | 20,701,283 |
| Avg 30 Day Volume | 0 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | -0.0 |
| Price to Sales | 22.08 |
| Price to Book Ratio | 11.04 |
| Enterprise Value to Revenue | -3.88 |
| Enterprise Value to EBIT | 1.98 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Albireo Pharma Inc
CEO: Ronald Cooper Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product ...